This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera
Journal of Cancer Research and Clinical Oncology Open Access 22 November 2021
-
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Leukemia Open Access 03 September 2021
-
Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?
Leukemia Open Access 05 December 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.
Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96:1653–65.
Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. J Cancer Res Clin Oncol. 2016;142:2041–9.
Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016;97:192–200.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.
Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia 2018. (In press)
Kremyanskaya M, Najfeld V, Mascarenhas J, Hoffman R. The polycythemias. In: Hoffman R, editor. Hematology - Basic Principles and Practice. 6th ed: Philadelphia: Elsevier Saunders; 2013. p. 998–1033.
Labbe RF, Dewanji A. Iron assessment tests: transferrin receptor vis-a-vis zinc protoporphyrin. Clin Biochem. 2004;37:165–74.
Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem. 1994;40:768–73.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
FHH has served as an advisory board member for Novartis Inc., AH received research support from Novartis, BMS, Incyte and Pfizer. The other authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Heidel, F.H., Al-Ali, HK., Hirt, C. et al. Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia 32, 2085–2087 (2018). https://doi.org/10.1038/s41375-018-0214-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0214-x
This article is cited by
-
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera
Journal of Cancer Research and Clinical Oncology (2022)
-
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Leukemia (2021)
-
Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?
Leukemia (2019)
-
Risikoadaptierte Therapie chronischer BCR-ABL1-negativer myeloproliferativer Neoplasien
Der Onkologe (2019)
-
Risikoadaptierte Therapie chronischer BCR-ABL1-negativer MPN*
InFo Hämatologie + Onkologie (2019)